- Home
- Companies
- north america
- therapeutic potential
Show results for
Refine by
Therapeutic Potential Suppliers In North America
31 companies found
based inHackensack, NEW JERSEY (USA)
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development ...
based inMontreal, QUEBEC (CANADA)
As a specialty therapeutics, clinical-stage biotech company, Inversago Pharma develops new generations of peripherally-acting cannabinoid-1 receptor (CB1) inverse agonists for the treatment of diabetic kidney disease, type 1 and type 2 diabetes, ...
Inversago Pharma Inc. is focused on the development of peripherally-acting CB1 receptor (CB1) inverse agonists for the treatment of diabetic nephropathy, NASH, type 1 diabetes and Prader-Willi Syndrome. While previous generation of centrally-acting ...
based inCambridge, MASSACHUSETTS (USA)
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our ...
Sage stepped up to fill an innovation void by thinking differently about brain health disorders and how we approach the discovery and development of new ...
based inNew York, NEW YORK (USA)
Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We are dedicated to offering custom peptide synthesis, process development, GMP manufacturing as well as catalog products for customers in ...
The field of bioconjugation has had a considerable impact on academic research, clinical diagnostics and the production of therapeutics. Peptides are an important type of molecules for derivatization by bioconjugation. ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Proteolysis targeting chimera (PROTAC) drugs offer a novel approach to disease treatment by leveraging the body's innate protein degradation pathways. In contrast to traditional small-molecule inhibitors, PROTAC drugs promote the degradation of ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Bispecific T cell engaging receptors (TCER®) are off-the-shelf biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing specific tumor targets. The design of these novel ...
based inMalvern, PENNSYLVANIA (USA)
Since our founding in 2001, we have had one singular obsession: We strive to give our clients a personalized and collaborative research experience. We are here to help you find the answers you need to develop the best possible drug candidate for ...
ASH1L is a large , multi-domain protein associated with actively transcribed regions of chromatin, ASH1L is the human homolog of Drosophila Ash1, a Trithorax group protein. Like its counterpart in Drosophila, ASH1L contains a SET histone ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-704 is a ghrelin O-acyl transferase inhibitor with therapeutic potential for multiple ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for ...
based inNew York, NEW YORK (USA)
ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...
based inMountain View, CALIFORNIA (USA)
Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to ...
based inChicago, ILLINOIS (USA)
Our company began as Nymirum. As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules. We ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
EX VIVO Human Platforms for Cardiovascular Drug Discovery. Broadly defined, cardiovascular disease is the leading cause of death for men and women across most racial and ethnic groups in the United States with one person dying approximately every 34 ...
based inAustin, TEXAS (USA)
Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing ...
based inCambridge, MASSACHUSETTS (USA)
Since our founding in 2007, we’ve put tenacity and innovation to work to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal ...
based inSan Diego, CALIFORNIA (USA)
Capricor is Developing Transformative Cell and Exosome-based Therapeutics for the Treatment and Prevention of Diseases. Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and ...
based inSouth San Francisco, CALIFORNIA (USA)
Neurona Therapeutics is driven by rigorous scientific discovery and focused on developing breakthrough treatments for neurological disorders. Neurona Therapeutics is a privately-held, clinical-stage biotherapeutics company focused on discovering and ...
Chronic Disorders of the Nervous System are Prime Indications for Regenerative Medicine. Neurona is a clinical-stage biotherapeutics company developing regenerative cell therapies that permanently integrate into neural circuits, replace affected ...
based inSan Francisco, CALIFORNIA (USA)
Vetherapy is a team of scientists, bioengineers, veterinarians and entrepreneurs on a mission to bring stem cell therapies to treat complex and challenging diseases for pet. Vetherapy stem cell therapies are the result of nearly 2 decades of ...
based inMontreal, QUEBEC (CANADA)
eNUVIO three founders first met as graduate students in 2010, working together on an interdisciplinary collaboration between two university science labs in Montreal. At that time, it was obvious that they shared a strong interest for research tool ...